M3USA
The US arm of Japan's M3: physician panels, MDLinx and clinical trial sites, inside a cash-rich parent whose North American sales went flat last year while the rest grew.
M3, Inc. FY2025 results presentation (parent group)- Revenue
- $2.33B M3 group (parent), year to March 2026, up 23% in yen. M3USA does not report on its own.
- Profit
- +$488M group operating profit, up 17% in yen, a 21% margin.
- Debt
- $220M of group borrowings against $1.04B of cash.
- Watch
- Flat North America sales, about $203M, barely moved last year while Europe and Asia grew 11 to 13%.
- AI
- About 15% of group operating profit the parent credits to AI, with 100+ AI projects running.
- Staff
- About 17,000 across the M3 group in 18 countries. No US headcount is published.
- Hiring
- 63 → 67 remote listings since Oct 18.
Japan pays most of the bills.
These are the parent's segments. M3USA sits inside Overseas, which is about a quarter of group sales. North America was about $203M of Overseas last year; the rest is Europe and Asia. Most money is made in Japan.
- 1The biggest physician panel in the worldMore than 7 million doctor members and panelists, which M3 says covers about half of all doctors worldwide.M3 FY2026 Q1 presentation (as of June 2026)
- 2Already sells to every big drugmakerM3USA says its clients include all top 10 pharmaceutical companies and over 100 product brands.M3 USA, About us
- 3A full physician hiring stack in the USThe Medicus Firm (retained search for about 450 medical institutions), PracticeMatch, NAS Recruitment Innovation and the MDLinx Career Center.M3 Report for Investors 2025
M3USA brought in $565 million in 91 days.
That is about $25 million more than the same three months a year earlier. Each of its 17,000 employees brought in about $0.14 million over the year, about $380 a day.
Revenue is not profit. It is the money that came in before M3USA pays any of its costs.
M3, Inc. Q1 results; both quarters at 159.36 per USD (Fed H.10 Apr to Jun 2026 average) so growth matches yen; staff approx., group-wideOperating profit grew from $427 million to $488 million.
Revenue grew 47% in two years. In FY2025 (to Mar 2026) it kept 21 cents of every revenue dollar as operating profit.
- FY2023 (to Mar 2024): kept 27¢ of every $1
- FY2024 (to Mar 2025): kept 22¢ of every $1
- FY2025 (to Mar 2026): kept 21¢ of every $1
The parent owes little and holds a lot of cash, and says its latest deal was paid from cash on hand. M3USA's own balance sheet is not public.
What the filings say, and what we think it means.
The fact is the filing's. The read, in italics, is ours.
- 01Watch
US clinical trials took another write-down after vaccine policy shifted.
M3 FY2025 presentation, impairment detailsM3 booked JPY 4.6B (about $31M) of Overseas impairments in FY2025, citing project cancellations in US vaccine trials after policy changes, plus the UK doctor-careers unit. It had written down the US trials business before.
The trial-site business (M3 Wake Research) is the weak spot in the US. Roles tied to vaccine studies look less secure than research or recruiting roles.
- 02Watch
North America stood still while the rest of Overseas grew.
M3 FY2025 and FY2026 Q1 presentations, sales by region; dollar view uses Fed H.10 quarter averagesNorth America sales were JPY 30.52B in FY2025 against JPY 30.48B the year before. Europe and Asia grew 11 to 13%. In April to June 2026, North America rose about 8% in yen, which is slightly down in dollars.
The region M3USA lives in is not where the parent's growth is coming from. A weak yen flatters the reported numbers.
- 03Watch
The trial-site network looks smaller than it was.
M3 Report for Investors 2025; BioSpace, Oct 19, 2022In Oct 2022 M3 Wake Research had 23 locations. The parent's Nov 2025 investor report describes over 10 organized trial sites and facilities.
The two counts may be measured differently, so treat this as a question to ask, not a confirmed closure. Neither the company nor any WARN filing we found reports site layoffs.
- 04Watch
The year started below plan, mainly because of Overseas.
M3 FY2026 Q1 presentation, forecasts vs actualsApril to June 2026 revenue was JPY 90.1B (+4.5%) and operating profit JPY 18.1B (down 8.6%), short of M3's own plan of about JPY 95B and JPY 19B. Guidance for the half is +12.4%.
The second half has to do a lot of work. Results for July to September are due Nov 4, 2026, and will show whether the full-year target holds.
- 05Neutral
A one-time tax on overseas dividends cut quarterly profit by a fifth.
M3 FY2026 Q1 presentationQ1 profit fell 22% to JPY 10.6B while pretax profit fell only 5%. M3 says the quarter includes a one-time tax provision on dividends from overseas operations.
Our read: cash is being sent up from foreign units to the parent. That is normal, but it means profits made abroad are flowing to Tokyo rather than staying for local growth.
- 06Neutral
The parent has started buying back its stock.
M3 buyback status, Nov 2, 2026; FY2025 resultsM3 spent JPY 20B (about 11.7M shares) on buybacks in FY2025 and approved up to JPY 20B more from May 2026 to April 2027. By Oct 31, 2026 it had bought 2.78M shares for JPY 5.0B. Next year's dividend is still undecided.
Returning cash this way points to slower growth ahead. It also shrinks the share count, which helps anyone holding M3 options.
- 07Neutral
Stock options go to a few hundred people, not everyone.
M3 stock option notice, Aug 6, 2026; terms fixed Aug 21In Aug 2026 M3 granted options on 102,800 shares at JPY 1,884 to 277 employees and directors of wholly owned subsidiaries, usable from Aug 2028. Sixteen more people got options on 921,500 shares at a JPY 1 exercise price.
Equity is a perk for a small group. Whether any M3USA staff were included is not disclosed, so ask during an offer.
- 08Neutral
The only US office it lists is in Pennsylvania.
M3 USA About us and Leadership pages; Wake Research release, May 2022usa.m3.com lists 501 Office Center Drive, Fort Washington, PA, and a 202 (Washington DC) phone number. Raleigh, NC is the base of M3 Wake Research, the trial-site unit. Aki Tomaru is CEO of M3USA.
M3USA is a family of brands with different home bases, so where your team sits depends on the brand you join.
- 09Good
Built by buying, and the parent still buys about 10 companies a year.
M3 FY2026 Q1 presentation; usa.m3.com About; BioSpace, Oct 2022M3 entered the US by buying MDLinx in 2006. Wake Research joined in 2018. The parent says it keeps doing roughly 10 deals a year with no change in strategy.
A buyer with cash tends to add teams, not cut them. Integration after a deal is the usual time for role changes.
What the hiring data says.
We save every company's roles, pay by team and level, AI share and churn every day, so each month this page can say more. Sparklines use their own scale.
Can AI agents do business with M3USA?
We checked the agent payment programs, developer docs and site rules an AI assistant would meet.
Doors open, no agent tools. Readable sites, nothing built for agents.
Still Remote read- Not foundAgent payment or commerce protocols, MCP serversNo M3USA or M3 announcement found tying it to MCP, Google AP2/UCP or OpenAI agent checkout. It sells research and media to pharma, not checkouts.checked Nov 3, 2026
- Not foundAn llms.txt file for AI toolsusa.m3.com/llms.txt and corporate.m3.com/llms.txt return not found. m3globalresearch.com/llms.txt returns a normal web page, not a text index.checked Nov 3, 2026
- YesLets AI crawlers read the M3USA siterobots.txt names no AI bots. It blocks only /wp-admin/ for everyone and asks for a 10-second crawl delay.checked Nov 3, 2026
- MixedLets AI assistants read MDLinxA Sept 2026 policy in robots.txt allows search and user-triggered agents (ChatGPT-User, Claude-User, PerplexityBot) and blocks training crawlers like GPTBot and ClaudeBot. Bot protection still refused our plain page fetch.checked Nov 3, 2026
- YesJob listings open to AI assistantscareers.usa.m3.com allows every bot and publishes a sitemap.checked Nov 3, 2026
- AnnouncedIts own AI assistant for doctorsThe parent plans proprietary AI features on m3.com to answer clinical questions. That is Japan; no US version announced.M3 FY2025 presentation
Where M3USA puts AI to work.
- 1The parent says AI already earns real moneyM3 credits AI with about JPY 10B, roughly 15% of operating profit, from over 100 projects, and says internal AI use is growing more than 10x a year. Its mid-term aim is up to about half.M3 FY2026 Q1 presentation
- 2AI picks most of what doctors seeAbout 80% of the m3.com home page is AI-personalized content. Japan-side, but it is the playbook M3 runs on its physician sites.M3 FY2025 presentation
- 3Only about 1% of revenue seen as at risk from AIM3 names consumer Q and A (AskDoctors) and academic editing as the businesses AI hurts. No AI layoffs have been announced.M3 FY2025 presentation
As many listings as on Oct 17, led by operations.
The signals, and which way they push.
- HeadwindUS vaccine policy hit the trial sites.
Vaccine-trial cancellations drove a write-down of the US clinical trials business, and M3 says uncertainty there remains in 2026.
- HeadwindGrowth is happening elsewhere.
North America sales were flat in FY2025 while Europe and Asia grew double digits, and Q1 2026 missed plan mainly because of Overseas.
- TailwindUS doctor shortages feed the recruiting brands.
M3 points to AAMC projections of a growing US physician shortfall as the case for its career businesses (Medicus, PracticeMatch, NAS).
- TailwindA rich parent that keeps buying.
JPY 156B of cash, little debt and about 10 deals a year. The latest, WISEMAN in Japan, was paid from cash on hand.
- TailwindAI is a group-wide priority.
M3 rewrote its mission in June 2026 from Internet to technology, and says internal AI use is growing more than 10x a year.
Where M3USA ends up, if we had to bet.
Our calls, not facts. Each one is tied to something that already happened, so you can judge the reasoning.
- 1
M3USA adds at least two more US businesses by 2031.
Likely 72%M&AM3 built its US arm by buying MDLinx, Wake Research and recruiting firms, and still does about 10 deals a year. It has JPY 156B of cash and little debt.
M3 FY2026 Q1 presentation; FY2025 results - 2
M3 sells or sharply shrinks its US trial-site business by 2032.
Coin flip 50%RestructuringThe US clinical trials unit has been written down more than once, most recently after vaccine cancellations. Its site count looks lower than the 23 locations of 2022.
M3 FY2025 presentation; Report for Investors 2025 - 3
North America stays the slowest-growing Overseas region through 2031.
Likely 72%GrowthIt was flat in FY2025 while Europe and Asia grew 11 to 13%. The parent's new growth bets (Limbic in Australia, VIDAL in France, India education) are outside the US.
M3 FY2025 presentation - 4
M3 credits AI with a third or more of group operating profit by 2032.
Coin flip 50%AIIt went from about 5% in FY2021 to about 15% in FY2025 and aims for up to about half. The figure is M3's own estimate, so the claim is easier to make than to check.
M3 FY2026 Q1 presentation - 5
AI assistants take a real share of US doctors' reading time from portals like MDLinx.
Coin flip 50%CompetitionMDLinx moved in Sept 2026 to block AI training crawlers while letting answer engines in, a sign it sees both threat and traffic. M3 argues its Japanese site is safe because about 99% of visits come direct.
MDLinx robots.txt; M3 FY2025 presentation
Read by the Still Remote research agent on November 3, 2026 from the sources linked on this page. Facts and scenarios only, not investment advice.